Obtaining More Accurate Signals: Spatiotemporal Imaging of Cancer Sites Enabled by a Photoactivatable Aptamer-Based Strategy
Source abstract
Abstract
Early cancer diagnosis is of great significance to relative cancer prevention and clinical therapy, and it is crucial to efficiently recognize cancerous tumor sites at the molecular level. Herein, we proposed a versatile and efficient strategy based on aptamer recognition and photoactivation imaging for cancer diagnosis. This is the first time that a visible light-controlled photoactivatable aptamer-based platform has been applied for cancer diagnosis. The photoactivatable aptamer-based strategy can accurately detect nucleolin-overexpressed tumor cells and can be used for highly selective cancer cell screening and tissue imaging. This strategy is available for both formalin-fixed paraffin-embedded tissue specimens and frozen sections. Moreover, the photoactivation techniques showed great progress in more accurate and persistent imaging to the use of traditional fluorophores. Significantly, the application of this strategy can produce the same accurate results in tissue specimen analysis as with classical hematoxylin-eosin staining and immunohistochemical technology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Biosensors and Analytical Detection · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Research Center for Tissue Engineering and Regenerative Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P.R. China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China
References (37)
Show source-provided references
1. 10.1021/cr300468w10.1021/cr300468w ↗
2. 10.2144/00011338210.2144/000113382 ↗
3. 10.1073/pnas.050882110210.1073/pnas.0508821102 ↗
4. 10.1016/j.cbpa.2006.04.00310.1016/j.cbpa.2006.04.003 ↗
5. 10.1021/cr030183i10.1021/cr030183i ↗
6. 10.1038/nm0498-46710.1038/nm0498-467 ↗
7. 10.1038/nnano.2011.10110.1038/nnano.2011.101 ↗
8. 10.1021/ar500078f10.1021/ar500078f ↗
9. 10.1073/pnas.142010511110.1073/pnas.1420105111 ↗
10. 10.1002/anie.20130570710.1002/anie.201305707 ↗
11. 10.1002/anie.20130884310.1002/anie.201308843 ↗
12. 10.1021/ac070055k10.1021/ac070055k ↗
13. 10.1021/ac802092j10.1021/ac802092j ↗
14. 10.1039/C5SC02565F10.1039/C5SC02565F ↗
15. 10.1039/c0sc00647e10.1039/c0sc00647e ↗
16. 10.1021/ac503723610.1021/ac5037236 ↗
17. Hicke B. J. · J. Nucl. Med. · 2006 · 47 · 668
18. 10.1038/nbt.246810.1038/nbt.2468 ↗
19. 10.1016/j.cbpa.2003.08.00710.1016/j.cbpa.2003.08.007 ↗
20. 10.1146/annurev.ph.55.030193.00354310.1146/annurev.ph.55.030193.003543 ↗
21. 10.1016/S0076-6879(98)91007-210.1016/S0076-6879(98)91007-2 ↗
22. 10.1016/S0962-8924(99)01585-810.1016/S0962-8924(99)01585-8 ↗
23. 10.1016/S0960-9822(99)80136-510.1016/S0960-9822(99)80136-5 ↗
24. 10.1021/ar200021p10.1021/ar200021p ↗
25. 10.1016/j.bmc.2010.07.01110.1016/j.bmc.2010.07.011 ↗
26. 10.1021/ja070376d10.1021/ja070376d ↗
27. 10.1021/ja212125w10.1021/ja212125w ↗
28. 10.1038/nmeth73010.1038/nmeth730 ↗
29. 10.1039/c2sc20764h10.1039/c2sc20764h ↗
30. 10.1016/j.yexmp.2009.01.00410.1016/j.yexmp.2009.01.004 ↗
31. Ginisty H. · J. Cell Sci. · 1999 · 112 · 76110.1242/jcs.112.6.761 ↗
32. Srivastava M. · FASEB J. · 1999 · 13 · 191110.1096/fasebj.13.14.1911 ↗
33. Derenzini M. · Lab. Invest. · 1995 · 73 · 497
34. 10.1182/blood-2006-08-04325710.1182/blood-2006-08-043257 ↗
35. 10.1002/cm.1006010.1002/cm.10060 ↗
36. 10.1074/jbc.271.10.569810.1074/jbc.271.10.5698 ↗
37. 10.1021/ac051760110.1021/ac0517601 ↗